Analyzing NRx Pharmaceuticals (NASDAQ:NRXP) & Biostar Pharmaceuticals (OTCMKTS:BSPM)

Biostar Pharmaceuticals (OTCMKTS:BSPM) and NRx Pharmaceuticals (NASDAQ:NRXP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Profitability

This table compares Biostar Pharmaceuticals and NRx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biostar Pharmaceuticals	N/A	N/A	N/A
NRx Pharmaceuticals	N/A	N/A	-449.16%

Earnings and Valuation

This table compares Biostar Pharmaceuticals and NRx Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biostar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NRx Pharmaceuticals	N/A	N/A	-$30.15 million	($2.41)	-0.85

Analyst Recommendations

This is a summary of current ratings for Biostar Pharmaceuticals and NRx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biostar Pharmaceuticals	0	0	0	0	0.00
NRx Pharmaceuticals	0	0	4	1	3.20

NRx Pharmaceuticals has a consensus target price of $28.25, suggesting a potential upside of 1,284.80%. Given NRx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Biostar Pharmaceuticals.

Insider and Institutional Ownership

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 17.2% of Biostar Pharmaceuticals shares are owned by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Biostar Pharmaceuticals has a beta of -2.17, meaning that its share price is 317% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Summary

NRx Pharmaceuticals beats Biostar Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

About Biostar Pharmaceuticals

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.